Official UK Coronavirus reporting ends

Introduction I have continued to run my own Coronavirus model, my recent prior report on February 9th this year having immediately followed the outbreak of the “Kraken” variant, Omicron XBB.1.5, in the UK. This brief post provides my own latest charts from my model, in the light of cessation of the UK Government’s own CovidContinue reading “Official UK Coronavirus reporting ends”

The Kraken Wakes*

I have continued to improve and run my Coronavirus model daily. The code for the model is now at version 172, and I have added a dataset to represent the variant XBB.1.5, known informally as “Kraken”. The fit of the model to reported deaths is good. I explore in the article the behaviour of Modelled vs. Reported Active Cases.

Omicron continues to surprise

Introduction In my most recent articles on the Omicron variants of Covid-19, I have highlighted the discrepancy between plummeting Active Cases and increasing cumulative Deaths. My model draws attention to this, by comparing the previous alignment of modelled and reported data, prior to February 24th, with the recent divergence. This post continues to summarise theContinue reading “Omicron continues to surprise”

Declining Omicron cases but increasing deaths

Something odd seems to be happening with the relationship between reported UK Covid-19 cases and deaths in the last few weeks, when deaths have been increasing somewhat more quickly than recently, but cases have declined steeply. My model charts seem to expose this oddity.

They think it’s all over – but it isn’t

In this article, I present a few variations of the current model to illustrate some outcomes depending on different assumptions about the current dominant variant, Omicron BA.2; they are fairly consistent in their forecasts over the 1400 day period of the model, from the outset in February 2020 to December 2023, and show that as NPIs are removed, vaccination is what keeps us safe.

Omicron BA.2, vaccination for 5-11 year-olds, and the honeymoon period

I haven’t needed to make significant updates to my Coronavirus model for a while, because it has been working well.
The original Omicron variant morphed into the new BA.2 variant, and although it seems no more dangerous than its predecessor, it is thought to be between 33%-50% more transmissible. I have assumed the lower value of 33% more transmissive for this post.
I have added Omicron BA.2 as fifth variant v5 to my model, with 8 times the transmissibility of Delta, compared with the original Omicron variant v4 in the model, at 6 times the Delta transmission rate.

Omicron modelling update

I have run updates to my model for lower and medium vaccine efficacy to Omicron, and lower, medium and higher virulence and mortality, and continue to compare with reported data. While evidence is still in short supply, nothing has firmly contradicted the impression that Omicron is highly transmissive, as well as being possibly less virulent.

Just as we thought it was safe to go back into the water

Omicron is feared to have higher infectiousness than the Delta variant, with even greater concerns should it turn out to cause more severe symptoms, higher mortality, and possibly worst of all, if it were able to evade current Covid-19 vaccines. I have made some parametric runs of my model to assess the possible effects.

Pandemic modelling review

Vaccination has somewhat stabilised the SARS-Cov-2 pandemic in the UK. I summarise the capabilities that I have found necessary and useful in modelling the behaviour of the pandemic; successive variants, different population age-groups, the effect of Government NPIs, and vaccinations.

Booster jab matters

Having just had my 3rd Covid jab, the “booster” jab, it provoked a few thoughts about that, my Coronavirus model, and the wider scene. I had incorporated multiple jabs into my UK model some time ago, and multiple phases for inoculation volumes to cope with the first and second jabs. I am taking this opportunity to report briefly on model outcomes for waning immunity in the context of booster jabs.